Dr. Reddy’s Laboratories (NYSE:RDY) Announces Quarterly Earnings Results

Dr. Reddy’s Laboratories (NYSE:RDY) issued its quarterly earnings data on Thursday. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01, Zacks reports. Dr. Reddy’s Laboratories had a return on equity of 18.53% and a net margin of 17.81%.

Dr. Reddy’s Laboratories Stock Down 1.0 %

Shares of NYSE RDY opened at $14.02 on Friday. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The company has a market cap of $11.70 billion, a price-to-earnings ratio of 22.39 and a beta of 0.51. Dr. Reddy’s Laboratories has a 12-month low of $13.61 and a 12-month high of $16.89. The firm’s 50-day simple moving average is $14.86 and its 200 day simple moving average is $15.52.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Finally, Barclays dropped their price target on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.